Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Verizon

The stock market for the most part has had a solid year after a dreadful 2022, and those that owned any of the Magnificent 7 have had an incredible year.

These 3 Demolished ‘Strong Buy' Dividend Stocks Are the Cheapest in Over 7 Years

Altria

Market volatility in 2023 has made some equities overvalued and other undervalued. Investors have fled some sectors and industries because their results are sensitive to inflation and rapidly rising interest rates.

3 High-Yield Stocks for Long-Term Income

AbbVie

Amgen

Franklin Resources

Chevron

Helmerich & Payne

Old Republic International

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

Best Retirement Stocks to Buy Now

Rite Aid

Rite Aid Corp

These pharmacy retailers have a lot in common, as both have struggled to stay out of the red. Walgreens remains unprofitable, but it is making efforts to reduce even more costs.

Rite Aid Files for Bankruptcy: Is Walgreens Boots Alliance Headed for the Same Fate?

Boeing

Disney

Boeing is generating much stronger free cash flow with demand for its airplanes increasing. Disney could enjoy a catalyst if it can forge a good partnership for its ESPN business.

These 3 Dow Jones Stocks Could Soar 19% to 29% Over the Next 12 Months, According to Wall Street

Retail locations will offer 7-day-a-week availability of healthcare providers HARTFORD, Conn., Oct. 24, 2023 /PRNewswire/ -- Walgreens and Hartford HealthCare will add health clinics to select Walgreens locations in Connecticut, advancing a unique retail health model based on convenience, access to care, affordability and health equity.

Hartford HealthCare and Walgreens partner to provide health clinics that improve access to care

Rivian Automotive

United Continental Hlds

Walgreens Boots Alliance faces a tough road ahead as it looks to stay out of the red and grow its healthcare business. Rivian Automotive posts billion-dollar losses with regularity because the business is nowhere near breaking even.

3 Struggling Stocks That Are Overdue for Steep Downgrades

Salesforce

Markets were mixed on Monday, with the Dow losing ground. Shares of Walgreens benefited from favorable comments from stock analysts.

These 2 Dow Stocks Got Wall Street's Attention on Monday

Some pharmacy workers at Walgreens, one of the nation's largest drugstore chains, say they are planning another walkout at the end of October, and organizers are hoping this time the protest spreads nationwide.

Some Walgreens pharmacy workers say they are planning another walkout. Here are their reasons why

J.P. Morgan analysts are optimistic about Walgreen's newest CEO saying they are encouraged by his expertise in healthcare services like leading Cigna's health services organization.

Walgreens stock gets a boost after JP Morgan expresses confidence in new CEO

Walgreens Boots Alliance Inc (NASDAQ:WBA) stock is up 3.7% to trade at $22.05 at last check, after a J.P.

Upgrade Helps Walgreens Stock Off Record Lows

JPMorgan upgraded WBA stock to buy early Monday, expecting Walgreens' new CEO to usher in "a new era" for the Dow Jones pharmacy giant.

WBA Stock Jumps On Upgrade, Target Hike. New CEO, 'New Era' Analyst Says

Walgreens' new CEO, Tim Wentworth, has extensive healthcare experience and may help accelerate the company's transition into a full healthcare company. Q4 earnings showed impressive sales growth in the US and internationally, but a looming recession may impact future expectations. The company's dividend may be at risk due to declining free cash flow and the possibility of additional lawsuits and store closures.

Walgreens Q4 Earnings: The Dividend Is On Life Support (Rating Downgrade)

Shares of Walgreens Boots Alliance Inc. rallied Monday after J.P. Morgan turned bullish on the healthcare services and pharmacy chain, based on the expectation that the new chief executive will help remove the overhangs that have been hurting the stock.

Walgreens' stock extends bounce off 25-year low as new CEO prompts rare bullish call

CVS Health

It's been quite a week for pharmacy news. Pharmacies are facing numerous challenges as fall progresses—just in time for cold and flu season.

CVS pharmacy pulls oral phenylephrine cold medicines from shelves. Will Walgreens and others follow?

Bristol-Myers

Johnson & Johnson

Eli Lilly

McKesson

Procter & Gamble

This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.

7 Healthcare Stocks That Can Cure a Lackluster Portfolio

Walgreens Boots Alliance Inc (NASDAQ:WBA) has agreed to pay $192.5 million to settle a class action lawsuit brought on by Rite Aid (NYSE:RAD) investors, according to a deal filed in Pennsylvania federal court on Wednesday. The deal is subject to approval by District Judge Jennifer Wilson.

Walgreens pays $192.5M to settle Rite Aid investors' lawsuit

Walgreens Boots Alliance has agreed to pay $192.5 million to settle a class action lawsuit by investors in Rite Aid who accused Walgreens of misleading them in 2017 about scrutiny of the two drugstore chain operators' then-pending merger.

Walgreens to settle Rite Aid investors' merger claims for $192 million

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens launched the 2023-2024 Walgreens Flu Index today to help communities track flu activity in their area and serve as an important reminder to take preventive measures, including an annual flu shot. Walgreens has produced this online, interactive tool for 10 flu seasons to show trends in flu activity week-over-week. The Walgreens Flu Index shows that, to date, overall flu activity is 66% lower compared to the start of the 2022-2023 flu season, with activ.

Walgreens Flu Index Shows Flu Activity Steadily Climbing This Season

A healthcare and pharmaceutical benefits manager veteran is coming in to lead the turnaround.

In Need of a Turnaround: Will Walgreens' New CEO Cut or Spare Its High-Yield Dividend?

Pharmacists say increased workloads and cut hours are the perfect recipe for medication errors, which can be fatal

US pharmacy workers strike over ‘dangerous' workloads as CVS and Walgreens rake in profits

Realty Income Corp

Exxon Mobil

In a dynamic investment landscape where financial stability and consistent returns are prized, the allure of dividend aristocrats is undeniable. These companies have mastered the art of maintaining dividends and increasing them year after year.

3 Dividend Aristocrats Guaranteed to Boost Your Portfolio's Power

Walgreens reported revenue growth last quarter but its bottom line was still in the red. The company plans to achieve $1 billion in cost savings during the next fiscal year.

Can Walgreens Boots Alliance Turn Things Around for Its Investors?

DEERFIELD, Ill. & NEW YORK--(BUSINESS WIRE)--Walgreens and the Cardiovascular Research Foundation (CRF) today announced a collaboration to drive forward the PREVUE-VALVE study, a groundbreaking population-based clinical trial that aims to quantify the prevalence of valvular heart disease (VHD) among older Americans and pave the way for the development of new therapies and tools for VHD detection and diagnosis. Walgreens aims to leverage its national presence, strong community relationships and.

Walgreens and the Cardiovascular Research Foundation Unite to Improve Recognition and Diagnosis of Valvular Heart Disease for Older Americans

UnitedHealth Group

Both Walgreens Boots Alliance and UnitedHealth Group recently reported quarterly results. Walgreens Boots Alliance didn't raise its dividend this year at the usual time, but at recent share prices, its payout yields more than 8%.

News for Walgreens Stock (WBA)